There is a right way and a wrong way to inform a patient about a switch from the reference product to a biosimilar, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Switching from a medication that is working to a biosimilar can make some patients nervous but educated patients feel more confident in the switch, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn's & Colitis Foundation.
Transcript
What is the best way to inform a patient that a switch to a biosimilar is happening?
The patients who we've focus grouped and talk to about how they want to be informed, they don't want to receive a letter from their insurance company, stating that “you're being switched.” They really want to have the opportunity to talk to their physician about this change and to be educated. I've been advocating with insurers that they leverage the resources—whether they be the FDA’s resources, whether they be resources like the Crohn's and Colitis Foundation resources, or other organizations that are working to educate their communities about biosimilars.
We know that when patients are educated and have an opportunity to hear from another patient—so the patient storytelling of other patients who have moved from their originator product to a biosimilar—they feel more confident in that. They feel more confident when their physician is educating them and telling them about the switch rather than a form letter sent to them from their insurance company. So, the more we can do this in an engagement way rather than just informing them about a change, the better the outcomes for the patient, the more patients that will be stable on their biosimilar and won't experience the nocebo effect, which we all want to avoid.
If you're needing to educate your patients or even your health care professional community about biosimilars, the Crohn's and Colitis Foundation has numerous resources, including some short format videos that really break down the language of biosimilars, the evidence supporting biosimilars in patient-friendly terms and they're available through our website. And they're less than 5 minutes long, and patients and their caregivers can view them and become more comfortable with the language of biosimilars and understanding how safe and effective they are.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Mental Health Diagnoses, Care Challenges Rise Among US Youth, Report Finds
April 26th 2024While behavioral health care utilization has been rising, the treatment landscape has been worsening. New findings show that 20% of youths did not receive any form of treatment within 3 months of their initial behavioral health diagnosis.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen